AIRLINK 208.80 Decreased By ▼ -2.17 (-1.03%)
BOP 10.28 Decreased By ▼ -0.39 (-3.66%)
CNERGY 6.93 Decreased By ▼ -0.48 (-6.48%)
FCCL 34.23 Increased By ▲ 0.66 (1.97%)
FFL 17.66 Decreased By ▼ -0.75 (-4.07%)
FLYNG 23.70 Increased By ▲ 0.08 (0.34%)
HUBC 132.42 Increased By ▲ 1.03 (0.78%)
HUMNL 14.01 Decreased By ▼ -0.09 (-0.64%)
KEL 4.93 Decreased By ▼ -0.05 (-1%)
KOSM 7.04 Decreased By ▼ -0.12 (-1.68%)
MLCF 44.70 Increased By ▲ 0.94 (2.15%)
OGDC 212.50 Decreased By ▼ -1.06 (-0.5%)
PACE 7.21 Decreased By ▼ -0.24 (-3.22%)
PAEL 39.78 Decreased By ▼ -1.75 (-4.21%)
PIAHCLA 17.32 Decreased By ▼ -0.15 (-0.86%)
PIBTL 8.45 Decreased By ▼ -0.15 (-1.74%)
POWERPS 12.50 Decreased By ▼ -0.01 (-0.08%)
PPL 184.75 Decreased By ▼ -4.85 (-2.56%)
PRL 41.55 Decreased By ▼ -2.76 (-6.23%)
PTC 24.60 Decreased By ▼ -0.37 (-1.48%)
SEARL 102.65 Decreased By ▼ -0.72 (-0.7%)
SILK 1.04 Increased By ▲ 0.01 (0.97%)
SSGC 38.12 Decreased By ▼ -2.38 (-5.88%)
SYM 18.75 Decreased By ▼ -0.77 (-3.94%)
TELE 9.06 Decreased By ▼ -0.38 (-4.03%)
TPLP 13.10 Decreased By ▼ -0.40 (-2.96%)
TRG 63.99 Decreased By ▼ -0.48 (-0.74%)
WAVESAPP 10.40 Decreased By ▼ -0.50 (-4.59%)
WTL 1.59 Decreased By ▼ -0.06 (-3.64%)
YOUW 4.15 Decreased By ▼ -0.06 (-1.43%)
BR100 11,940 Decreased By -251.2 (-2.06%)
BR30 35,909 Decreased By -673.8 (-1.84%)
KSE100 115,270 Decreased By -985.5 (-0.85%)
KSE30 36,250 Decreased By -353.8 (-0.97%)

The European Union's drug regulator said on Monday it could issue "within weeks" a decision on whether to approve the use of Pfizer's COVID-19 pill, Paxlovid, after the US drugmaker submitted an application seeking authorisation.

The approval sought is for the treatment of mild-to-moderate COVID-19 in patients 12 years of age and older, weighing at least 40 kilograms and are at high risk of their illness worsening, the European Medicines Agency said.

While vaccines are central to the fight against the pandemic, regulators are looking at therapies as a new tool against the fast-spreading Omicron variant, which has now been detected in more than 128 countries around the world.

The EMA has already evaluated a portion of the data during a rolling review of Pfizer's pill that began in November.

Britain approves Pfizer's antiviral COVID-19 pill

Pfizer's two-drug regimen called Paxlovid, which is meant to be taken at home for five days soon after onset of COVID-19 symptoms, was authorized for people aged 12 and older by the US Food & Drug Administration in December.

In a clinical trial, it was nearly 90% effective in preventing hospitalizations and deaths in patients at high risk of severe illness.

Comments

Comments are closed.